vs
Amphastar Pharmaceuticals, Inc.（AMPH）とKodiak Gas Services, Inc.（KGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Kodiak Gas Services, Inc.の直近四半期売上が大きい（$332.9M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 7.4%、差は5.9%）。Kodiak Gas Services, Inc.の前年同期比売上増加率が高い（7.5% vs -1.8%）。Kodiak Gas Services, Inc.の直近四半期フリーキャッシュフローが多い（$142.0M vs $24.6M）。過去8四半期でKodiak Gas Services, Inc.の売上複合成長率が高い（24.3% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
コディアック・ガス・サービス社は北米を中心に事業を展開する天然ガス圧縮サービスの大手プロバイダーで、石油・ガス産業の上流・中流事業者向けに、カスタマイズされた圧縮装置、保守サポート、運用支援を提供し、陸上天然ガスの採取・処理・輸送の効率向上を支援している。
AMPH vs KGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $332.9M |
| 純利益 | $24.4M | $24.6M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 26.1% |
| 純利益率 | 13.3% | 7.4% |
| 売上前年比 | -1.8% | 7.5% |
| 純利益前年比 | -35.7% | 29.0% |
| EPS（希薄化後） | $0.51 | $0.30 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $332.9M | ||
| Q3 25 | $191.8M | $322.7M | ||
| Q2 25 | $174.4M | $322.8M | ||
| Q1 25 | $170.5M | $329.6M | ||
| Q4 24 | $186.5M | $309.5M | ||
| Q3 24 | $191.2M | $324.6M | ||
| Q2 24 | $182.4M | $309.7M | ||
| Q1 24 | $171.8M | $215.5M |
| Q4 25 | $24.4M | $24.6M | ||
| Q3 25 | $17.4M | $-14.0M | ||
| Q2 25 | $31.0M | $39.5M | ||
| Q1 25 | $25.3M | $30.4M | ||
| Q4 24 | $38.0M | $19.1M | ||
| Q3 24 | $40.4M | $-5.6M | ||
| Q2 24 | $37.9M | $6.2M | ||
| Q1 24 | $43.2M | $30.2M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 37.5% | ||
| Q2 24 | 52.2% | 36.5% | ||
| Q1 24 | 52.4% | 39.4% |
| Q4 25 | 19.4% | 26.1% | ||
| Q3 25 | 13.2% | 19.9% | ||
| Q2 25 | 24.2% | 30.9% | ||
| Q1 25 | 21.9% | 27.1% | ||
| Q4 24 | 24.2% | 22.3% | ||
| Q3 24 | 29.8% | 20.4% | ||
| Q2 24 | 30.3% | 17.5% | ||
| Q1 24 | 27.9% | 27.9% |
| Q4 25 | 13.3% | 7.4% | ||
| Q3 25 | 9.0% | -4.3% | ||
| Q2 25 | 17.8% | 12.2% | ||
| Q1 25 | 14.8% | 9.2% | ||
| Q4 24 | 20.4% | 6.2% | ||
| Q3 24 | 21.1% | -1.7% | ||
| Q2 24 | 20.8% | 2.0% | ||
| Q1 24 | 25.1% | 14.0% |
| Q4 25 | $0.51 | $0.30 | ||
| Q3 25 | $0.37 | $-0.17 | ||
| Q2 25 | $0.64 | $0.43 | ||
| Q1 25 | $0.51 | $0.33 | ||
| Q4 24 | $0.74 | $0.18 | ||
| Q3 24 | $0.78 | $-0.07 | ||
| Q2 24 | $0.73 | $0.06 | ||
| Q1 24 | $0.81 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $3.2M |
| 総負債低いほど良い | $608.7M | $2.6B |
| 株主資本純資産 | $788.8M | $1.2B |
| 総資産 | $1.6B | $4.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 2.12× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $3.2M | ||
| Q3 25 | $276.2M | $724.0K | ||
| Q2 25 | $231.8M | $5.4M | ||
| Q1 25 | $236.9M | $1.9M | ||
| Q4 24 | $221.6M | $4.8M | ||
| Q3 24 | $250.5M | $7.4M | ||
| Q2 24 | $217.8M | $3.9M | ||
| Q1 24 | $289.6M | $9.3M |
| Q4 25 | $608.7M | $2.6B | ||
| Q3 25 | $608.6M | $2.6B | ||
| Q2 25 | $607.7M | $2.5B | ||
| Q1 25 | $603.9M | $2.6B | ||
| Q4 24 | $601.6M | $2.6B | ||
| Q3 24 | $596.4M | $2.6B | ||
| Q2 24 | $586.9M | $2.5B | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.2B | ||
| Q3 25 | $776.7M | $1.3B | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.4B | ||
| Q4 24 | $732.3M | $1.4B | ||
| Q3 24 | $727.7M | $1.4B | ||
| Q2 24 | $713.3M | $1.5B | ||
| Q1 24 | $672.4M | $1.1B |
| Q4 25 | $1.6B | $4.3B | ||
| Q3 25 | $1.7B | $4.4B | ||
| Q2 25 | $1.6B | $4.4B | ||
| Q1 25 | $1.6B | $4.4B | ||
| Q4 24 | $1.6B | $4.4B | ||
| Q3 24 | $1.5B | $4.5B | ||
| Q2 24 | $1.5B | $4.4B | ||
| Q1 24 | $1.6B | $3.3B |
| Q4 25 | 0.77× | 2.12× | ||
| Q3 25 | 0.78× | 2.08× | ||
| Q2 25 | 0.80× | 1.89× | ||
| Q1 25 | 0.80× | 1.91× | ||
| Q4 24 | 0.82× | 1.88× | ||
| Q3 24 | 0.82× | 1.86× | ||
| Q2 24 | 0.82× | 1.71× | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $194.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $142.0M |
| FCFマージンFCF / 売上 | 13.4% | 42.7% |
| 設備投資強度設備投資 / 売上 | 4.5% | 15.9% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 7.91× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $284.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $194.9M | ||
| Q3 25 | $52.6M | $113.4M | ||
| Q2 25 | $35.6M | $177.2M | ||
| Q1 25 | $35.1M | $114.3M | ||
| Q4 24 | $29.0M | $118.5M | ||
| Q3 24 | $60.0M | $36.9M | ||
| Q2 24 | $69.1M | $121.1M | ||
| Q1 24 | $55.3M | $51.5M |
| Q4 25 | $24.6M | $142.0M | ||
| Q3 25 | $47.2M | $10.9M | ||
| Q2 25 | $25.0M | $94.6M | ||
| Q1 25 | $24.4M | $36.8M | ||
| Q4 24 | $16.6M | $45.2M | ||
| Q3 24 | $46.2M | $-49.7M | ||
| Q2 24 | $63.1M | $4.0M | ||
| Q1 24 | $46.5M | $-8.6M |
| Q4 25 | 13.4% | 42.7% | ||
| Q3 25 | 24.6% | 3.4% | ||
| Q2 25 | 14.3% | 29.3% | ||
| Q1 25 | 14.3% | 11.2% | ||
| Q4 24 | 8.9% | 14.6% | ||
| Q3 24 | 24.1% | -15.3% | ||
| Q2 24 | 34.6% | 1.3% | ||
| Q1 24 | 27.1% | -4.0% |
| Q4 25 | 4.5% | 15.9% | ||
| Q3 25 | 2.8% | 31.7% | ||
| Q2 25 | 6.1% | 25.6% | ||
| Q1 25 | 6.3% | 23.5% | ||
| Q4 24 | 6.7% | 23.7% | ||
| Q3 24 | 7.2% | 26.7% | ||
| Q2 24 | 3.3% | 37.8% | ||
| Q1 24 | 5.1% | 27.9% |
| Q4 25 | 1.35× | 7.91× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 4.49× | ||
| Q1 25 | 1.39× | 3.76× | ||
| Q4 24 | 0.76× | 6.21× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 19.44× | ||
| Q1 24 | 1.28× | 1.70× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KGS
| Other Services | $126.8M | 38% |
| Other | $112.2M | 34% |
| Transferred At Point In Time | $93.8M | 28% |
